Literature DB >> 11927050

Structured Treatment Interruption: Approaches and Risks.

Mark Dybul1.   

Abstract

Although highly active antiretroviral therapy suppresses HIV replication resulting in extraordinary clinical benefits, toxicity, adherence difficulties, and the monetary cost of medications limit the long-term effectiveness and availability of therapy for many HIV-infected individuals. Strategies to interrupt therapy have been proposed as a means to enhance the sustainability of antiretroviral treatment. Widely different approaches with varied patient populations, theoretical concepts, and clinical designs are frequently lumped together as "structured treatment interruptions." This review summarizes the approaches and risks of treatment interruptions in HIV infection. Currently, none of these strategies can be recommended in standard clinical practice.

Entities:  

Year:  2002        PMID: 11927050     DOI: 10.1007/s11908-002-0059-2

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  47 in total

1.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Authors:  K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

2.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

3.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Authors:  V Miller; C Sabin; K Hertogs; S Bloor; J Martinez-Picado; R D'Aquila; B Larder; T Lutz; P Gute; E Weidmann; H Rabenau; A Phillips; S Staszewski
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

4.  High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

Authors:  A C McNeil; W L Shupert; C A Iyasere; C W Hallahan; J A Mican; R T Davey; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

5.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Authors:  G M Ortiz; D F Nixon; A Trkola; J Binley; X Jin; S Bonhoeffer; P J Kuebler; S M Donahoe; M A Demoitie; W M Kakimoto; T Ketas; B Clas; J J Heymann; L Zhang; Y Cao; A Hurley; J P Moore; D D Ho; M Markowitz
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

7.  Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.

Authors:  S A Kalams; P J Goulder; A K Shea; N G Jones; A K Trocha; G S Ogg; B D Walker
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.

Authors:  K V Heath; R S Hogg; K J Chan; M Harris; V Montessori; M V O'Shaughnessy; J S Montanera
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

9.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

10.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more
  4 in total

1.  Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia.

Authors:  Hasina Samji; Yalin Chen; Kate Salters; Julio S G Montaner; Robert S Hogg
Journal:  AIDS Behav       Date:  2014-11

2.  Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.

Authors:  Gilles Pialoux; Romina P Quercia; Hanne Gahery; Nathalie Daniel; Laurence Slama; Pierre-Marie Girard; Philippe Bonnard; Willy Rozenbaum; Véronique Schneider; Dominique Salmon; Jean-Gérard Guillet
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

3.  CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

Authors:  Jennifer Serwanga; Susan Mugaba; Auma Betty; Edward Pimego; Sarah Walker; Paula Munderi; Charles Gilks; Frances Gotch; Heiner Grosskurth; Pontiano Kaleebu
Journal:  AIDS Res Treat       Date:  2011-01-18

4.  Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Authors:  Emmanouil Papasavvas; Jay R Kostman; Karam Mounzer; Robert M Grant; Robert Gross; Cele Gallo; Livio Azzoni; Andrea Foulkes; Brian Thiel; Maxwell Pistilli; Agnieszka Mackiewicz; Jane Shull; Luis J Montaner
Journal:  PLoS Med       Date:  2004-12-28       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.